Novogen Limited (Nasdaq: NVGN) and CanTx Inc., its joint venture with Yale University, announced the success of proof-of-concept pre-clinical studies ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE